Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, May 6, 2017

Axim Signs Deal to Advance Clinical Trials of Cannabis-based MedChew Rx Gum to Treat MS Pain


                                                                  
  
Click here to receive MS news via e-mail


Axim Biotechnologies recently announced that its U.K. partner, Quay Pharmaceuticals, has secured licenses from the British Home Office to continue developing and importing its medical cannabinoid product MedChew Rx — a potential treatment for pain and spasticity in people with multiple sclerosis (MS), among other illnesses.
MedChew Rx is a gum containing 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC). The gum is intended to offer patients more consistent relief than existing cannabis-derived products that are smoked or eaten.
Continue reading



Then come back here to click this link: https://greenroadswellness.com/1236-2/

 which helps you to know more of CBD oil, CBD Capsules and CBD Cream (for pain)
   By the way, some use capsules to avoid the woody taste of the oil but did you know that the oil, used as a sub-lingual, works faster... 
       CBD by GreenRoads Wellness (GRW) is a Pharmacist Grade supplement
 



An Untreated Migraine Now Could Mean Chronic Migraines Later


                                                                  
  
Click here to receive MS news via e-mail

This article is not-MS related
Many with MS have other things wrong too
We hope this information might benefit those that need
Ignoring migraine pain with the hopes that it’ll just go away could lead to even more migraines later, according to a study.
Researchers looked at data from more than 4,600 people with episodic migraines—meaning 14 or fewer migraines days per month. Nearly half of the migraine sufferers received poor or very poor treatments, and these people were more likely to develop chronic migraines—15 or more migraine days a year—than those who received adequate treatment.
The researchers, who were from Montefiore Medical Center, Albert Einstein College of Medicine and Vedanta Research, also found that within a year, eight percent of those who received inadequate migraine treatment progressed to chronic migraines, compared to only 2.5% who received excellent treatment. The study was presented at the 2013 International Headache Congress.
What is Adequate Migraine Treatment?This raises the question, what is adequate migraine treatment? The answer is not black and white. Because no two people (and no two migraines) are the same, it’s important to work with your doctor to determine the best treatment approach for you. There are some commonalities, however, in all successful migraine treatment programs. They include:
  1. Knowing—and managing—your triggers. Because migraines affect people in very different ways, it’s important to be familiar with how they affect you specifically. This includes knowing what triggers your migrainegetting enough rest, and keeping stress levels low. This also means being your own advocate. Keep a migraine journal to track your pain and speak up to your doctor about the symptoms you’re experiencing. Not sure how to talk to your doctor about your headaches? Check out these suggestions from neurologist Mark Green, MD.
  2. Being proactive. One of the best ways to treat your migraine is to stop them before they start. As soon as you realize a migraine may be in the forecast, attempt to head it off. Make sure you take all prescribed medications before the pain becomes too debilitating.
  3. Knowing your options. There is no one specific migraine treatment that’s right for everyone. But knowing which options are available to you, whether it’s medication, natural remedies or even Botox, can help you start a dialogue with your doctor that could help craft your personal treatment plan.
  4. Building a team. Whether it’s friends and family, a neurologist, primary care physician, or counselor, make use of the supportive people around you. They can help keep you track and be on there on days when the migraine pain sidetracks you.




MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Friday, May 5, 2017

Cytomegalovirus Infection Worsens Multiple Sclerosis, Study in Mice Shows


                                                                  
  
Click here to receive MS news via e-mail


Cytomegalovirus Infection Worsens Multiple Sclerosis, Study in Mice Shows
A cytomegalovirus infection triggers an increase in inflammatory and cytotoxic immune cells in mice with multiple sclerosis (MS), which leads to enhanced inflammation and loss of nerve-protecting myelin.
A cytomegalovirus (CMV) infection leads to chronic activation of the immune system. One result is an increase in the number of immune cells called CD4+CD28null T-cells. High levels of this T-cell subgroup are associated with chronic inflammatory diseases.
Some previous studies have suggested a link between CMV infection and MS. But other studies have suggested that CMV-specific antibodies are associated with a better disease outcome, an increased age of disease onset, and decreased brain atrophy.
Researchers decided to see whether CMV is able to trigger an increase in CD4+CD28null T-cells, and how the infection impacts MS disease progression. The team used both mouse models and in vitro, or laboratory, work with human blood samples.
They observed that blood with a CMV infection had higher levels of CD4+CD28null T-cells than blood with no infection. The researchers also found that CMV peptides, or amino acids, increased the number of these cells in a lab.
CD4+CD28null T-cells are inflammatory, toxic cells found in MS lesions. Researchers discovered an increase in the cells in a mouse model of MS, and noted a correlation between the higher number and the severity of the disease. The used the established experimental autoimmune encephalomyelitis (EAE) mouse model of human MS.

MS Views and News
Providing educational information, resources and services for those affected by MS, globally


MS research on Stem Cell Transplants


                                                                  
  
Click here to receive MS news via e-mail



This is an exciting time for multiple sclerosis (MS) research. New technologies and insights are speeding the pace of discovery. In fact, there are more MS treatments in development now than ever before.
MS is a neurological disease that can cause extreme tiredness, vision changes, trouble moving, and other problems. Scientists are looking for ways to:
  • Stop the disease from getting worse
  • Restore lost function
  • Prevent and cure MS

Research Highlights

Besides testing new treatments, scientists continue to explore the root causes of MS. Much of the research is still being done in animals, but recent findings and ongoing research include:  
  • Bone marrow stem cell transplants that would offer long-term benefits
  • An epilepsy pill that slowed nerve damage
  • A specific type of training that improved memory and brain activity (as seen on MRI scans). Changes were still in place after 6 months.   
  • An experimental therapy in mice helped their bodies make myelin, a substance that protects nerves. The treatment is a type of microRNA, a small amount of genetic material.
  • A large team of researchers is analyzing gut bacteria to find out what role it may play as MS gets worse.
  • Researchers are studying children with MS to learn how their environment and genes make them more likely to get the disease. One early finding suggested low vitamin D levels were linked to MS relapses in kids with a specific gene.

Stem Cell Transplants
These are the only cells in your body with the power to create new types of cells. For example, your blood cells, brain cells, heart muscle, and bone all come from stem cells.
People who need new, healthy cells to fight a disease like cancer often get bone marrow stem cell transplants. This procedure can help rebuild your immune system by producing new blood cells. You might hear your doctor call it:
  • Stem cell transplant
  • Bone marrow transplant
  • HSCT (hematopoietic stem cell transplantation)
How does it work? Doctors remove and store cells from your body that make blood. Then, you take chemotherapy drugs to wipe out your immune system. After that, your stem cells go back in your body. They travel to your bone marrow, where they make new blood cells, giving your immune system a fresh start.
Studies show that bone marrow stem cell transplants might help some people with MS. However, the treatment is still experimental.

CONTINUE

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Immune-Based Therapy Shows Early Promise Against MS


                                                                  
  
Click here to receive MS news via e-mail



THURSDAY, April 20, 2017 (HealthDay News) -- An experimental immune-system therapy appears safe for people with progressive forms of multiple sclerosis. And it may ease symptoms in some, a preliminary study suggests.
The findings are based on just six patients, and the Australian researchers stressed that a lot of work still lies ahead.
But they were encouraged that this new approach to MS had no major side effects. In addition, three of the six patients showed symptom improvements, including reduced fatigue and better mobility.
It's not clear, however, what to make of those improvements, said Bruce Bebo, executive vice president of research for the National Multiple Sclerosis Society.
The study was a "phase 1" trial, meaning it was designed only to test the therapy's safety.
"Based on this very preliminary study, the therapy appears safe," said Bebo, who was not involved in the research.
"But I'd be even more cautious in drawing any conclusions about the clinical improvements," he stressed.
Larger, rigorous clinical trials are needed to show whether the treatment truly works, Bebo said.
READ MORE


MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Thursday, May 4, 2017

How to help kiss goodbye to multiple sclerosis


                                                                  
  
Click here to receive MS news via e-mail



Multiple sclerosis is on the rise in Australia – especially among young women. Here’s how you can raise funds to help find a cure.

The number of Australian teenagers and young women being diagnosed with multiple sclerosis (MS) is on the rise and no one knows why.
More than 23,000 Australians suffer MS and 76 per cent of them are female. More than 500 new cases are diagnosed here each year. And there are 2.3 million people with MS worldwide.
Tragically, the average age of diagnosis is just 30 (although you can get it at any age). 
MS is an autoimmune disease that causes the body to attack itself. While the cause is still unknown, experts believe genetic and lifestyle factors such as diet, exercise, vitamin D, sunlight and stress all play a role.
Australia – particularly Tasmania - has one of the highest rates of diagnosis in the world, leading scientists believe there is also a link between MS and distance from the equator. 
(You are seven times more likely to get MS if you were born in Tasmania versus tropical North Queensland. MS is also rarer in the Middle East, Asia or equatorial countries.)
“Evidence from here in Australia and overseas suggests that the incidence of MS is increasing,” says Dr Hamish Campbell, Research Development Co-ordinator at MS Research Australia. 
“Theories of why this increase is happening focuses on potential changes in lifestyle factors including, poorer diet and an increase in urbanisation leading to a decrease in outdoor activities.”
He says MS is most likely caused by a complex interaction between genetic and environmental risk factors which may include vitamin D deficiency, smoking, obesity and infection by the Epstein-Barr Virus.
Continue






MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Tuesday, May 2, 2017

Patients with MS Likely to Receive Depression Treatment


                                                                  
  
Click here to receive MS news via e-mail


Approximately 6 out of 10 ambulatory visits involving multiple sclerosis (MS) and depression recorded some form of depression treatment, a recent study found. A cross-sectional study was conducted by pooling multiple years (2005-2011) of National Ambulatory Medical Care Survey and the outpatient department of the National Hospital Ambulatory Medical Care Survey data. The final study sample was comprised of ambulatory visits among adults (aged ≥18 years) with MS and depression. Researchers found:
  • Between 2005 and 2011, approximately 2.1 million visits involved a diagnosis of MS and depression.
  • Depression treatment was observed in 57.25% of the sample.
  • Individuals who were aged ≥40 years were 81% less likely to receive depression treatment compared to those who were aged 18 to 39 years.
  • With the increase in each chronic condition, the likelihood of receiving depression treatment decreased by 44%.

READ MORE

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Increased Psoriasis Incidence in MS


                                                                  
  
Click here to receive MS news via e-mail


Psoriasis incidence and prevalence are higher in the multiple sclerosis (MS) population than in a matched population, a recent study found. Researchers used population-based administrative data to identify 4,911 persons with MS and 23,274 age- , sex- , and geographically-matched controls aged ≥20 years from 1998 through 2008. They found:
  • In 2008, the crude incidence of psoriasis per 100,000 person-years was 466.7 in the MS population, and 221.3 in the matched population.
  • The crude prevalence of psoriasis per 100,000 persons was 4,666.1 in the MS population, and 3,313.5 in the matched population.
  • The incidence and prevalence of psoriasis rose slightly over time.
  • After adjusting for sex, age at the index date, socioeconomic status, and physician visits, the risk of incident psoriasis was 54% higher in the MS population.
READ MORE


MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Treating MS with Vitamin D - Coimbra’s Protocol


                                                                  
  
Click here to receive MS news via e-mail

Coimbra’s Protocol Summary

Postby AntonioBR » Tue Dec 29, 2015 7:07 am



Coimbra’s Protocol Summary

Coimbra Protocol was developed by Dr. Cicero Galli Coimbra, a neurologist practicing in São Paulo, Brazil. 

The Coimbra Protocol is a therapeutic approach that relies on high doses of vitamin D to halt the misguided attacks of the immune system, and it has enabled thousands of patients around the world to keep their autoimmune diseases in permanent remission.



>> 
This Protocol requires the guidance and monitoring by a physician with specific training to analyze each particular case. 

There is a List of Doctors Worldwide here: http://www.thisisms.com/forum/coimbra-high-dose-vitamin-d-protocol-f57/topic27159.html

Some doctors work via Skype



Coimbra’s Protocol is used for: Multiple Sclerosis (all types of MS), Arthritis Rheumatoid, Lupus, Alopecia, Bronchitis, Charcot-Marie-Tooth, Depression, Atopic Depression, Crohn's Disease, Endometriosis, Fibromyalgia, Hypertension, Infertility, Psoriasis, Ménière Syndromes, ADEM Syndromes, Sjögren and Vitiligo.




Image

About Dr. Cicero Coimbra
Dr. Coimbra received his medical degree from the Universidade Federal do Rio Grande do Sul in 1979. He did two years of internal medical residency and two years of adult neurology residency at the Hospital de Clínicas de Porto Alegre, Brazil; followed by a year of fellowship training in pediatric neurology at Jackson Memorial Hospital, Miami. Coimbra earned his PhD in clinical neurology from the Federal University of São Paulo in 1990. He has also completed post PhD training in experimental brain ischemia at the Laboratory for Brain Research, University of Lund, Sweden. He is currently Associate Professor in the Department of Neurology and Neurosurgery, Federal University of Sao Paulo, UNIFESP. 


The making of a new protocol

Dr. Coimbra wanted to change lives, to treat neurological disorders. After his fellowship, Coimbra started doing experimental research by inducing ischemic brain damage in rats (in São Paulo, Brazil and Lund, Sweden) and testing different treatments to see what worked. Moderate hypothermia (body temperature reduced to 33 degrees Celsius) provided robust protection to the rat brain. Conversely, postischemic hyperthermia was detrimental, and could trigger a chronic neurodegenerative process. Administration of choline - a natural component of neuronal membranes - provided a moderate protection, suggesting that restricted availability of choline after transient brain ischemia was critical for cell membrane repair and consequent neuronal survival. 

"Seeing MS patients getting back to a normal life, young people no longer at risk of going blind or paraplegic - such experience gives great satisfaction to the doctor who has them under his/her care. It has been very gratifying." - Dr. Coimbra 

Following a general rule for research work, Coimbra needed to be as up to date as possible on the latest findings related to his field of interest (clinical neuroscience). He realized that much of the therapeutic progresses achieved from clinical and experimental research had not been moved to clinical practice. In spite of their immediate clinical applicability, these practices were not being taught in medical schools - even after several confirmatory reports. At a certain point Coimbra was convinced vitamin D would be a fundamental therapeutic resource, as it stimulates the production of several neuroregenerative substances in the brain. 

Coimbra began administering vitamin D in physiological doses (10,000 IU/day) to Parkinson's patients around the year 2001. He noticed that an extensive depigmented area on the forehead of one of his Parkinson's patients (who had also vitiligo - an autoimmune disorder) had virtually disappeared after 3 months on that daily dose. Searching the medical literature for the effects of vitamin D on the immune system revealed a significant number of published papers supporting a fundamental immunoregulatory role of that steroid, that vitamin D is actually a precursor of a powerful hormone that targets receptors in virtually all human cells to control a wide range of biological functions. Since MS is the most common neurological autoimmune disease and a major cause of incapacitating disabilities (like blindness, paraplegia) in young people, he decided to start treating MS patients in 2002 initially using similar doses of vitamin D. 


What is a physiological dose of vitamin D?

Coimbra believes that 10,000 IU/day of vitamin D is a physiological dose. This is the amount of vitamin D a young person makes if they are light skinned, wearing shorts and a t-shirt for about 20-30 minutes of mid-day sun. This daily dose is totally safe. No precautions are necessary. It is worth noting that the IOM indicated that 10,000 IU/day was considered the "NOAEL"--the 'no observed adverse effect level'. Coimbra calls the RDA a "paltry dose, although still officially recommended." 


Why does vitamin D work? 

The active form of vitamin D is the main regulator of the immune system. It empowers the innate immunity against microorganisms and suppresses autoimmunity (which is dependent on an abnormal "program" of immune activities known as "Th17", and is powerfully counteracted by vitamin D). Vitamin D also induces the proliferation of regulatory immune cells called "regulatory T lymphocytes." There is a vitamin D receptor (VDR) in every cell of the immune system. Vitamin D modifies the function of approximately 10% of human genes. 


What does Dr. Coimbra's protocol entail? 

Coimbra has been able to successfully suppress disease activity in about 95% of MS cases with variable (individually tailored) high daily doses of vitamin D. The doses are set according to the results of laboratory tests in order to compensate for that individual's degree of genetic vitamin D resistance. This resistance seems to underlie the predisposition to (and maintenance of) autoimmune aggression through the Th17 program of activities. As the protocol aims at regulating the immune system, it has been similarly effective in treating several other autoimmune diseases. 

He and his team of 5 doctors have treated more than 4,000 patients at his clinic in San Paulo City using the protocol. He has trained 27 physicians who have launched their own clinics in other cities of Brazil and other countries such as Argentina (2), Peru (1), Portugal (1), Spain (1), Italy (3), Croatia (1) and Canada (1). An ophthalmologist in Naples, FL has been recently trained and is preparing to start a research project using the same protocol to treat autoimmune diseases like uveitis - a major cause of blindness in the general population. 

The average initial dose for patients in this treatment protocol is about 1000 IU/day per kg of body weight. In addition to vitamin D, he also prescribes vitamin B2; a diet excluding calcium; and extra fluids (minimum 2.5L/day). After 2-3 months, the daily dose of vitamin D is adjusted in response to changes in laboratory test results. After one year the daily dose is further adjusted to compensate for adaptive changes of vitamin D metabolism (not unusual in patients receiving high doses), until a stable level of laboratory parameters is reached for that individual patient, the point at which vitamin D has reached its maximum immunological effect. This is usually achieved at the third or fourth medical appointment, after 2 years on vitamin D therapy. 

The blood work that Coimbra is most interested in is the parathyroid hormone (PTH). PTH production is inhibited by vitamin D and his research has shown that vitamin D immune benefit is maximized when circulating PTH has reached the lower limit of its normal (reference) range. Achieving that level of PTH requires variable daily doses of vitamin D because biological resistance to vitamin D is different for each person. PTH values are also used as a safety gauge, as vitamin D intoxication cannot occur if PTH is not fully suppressed. He carefully monitors blood and urinary calcium, to avoid kidney stones. A calcium restricted diet and minimal daily hydration of 2.5 L are imperative precautions to avoid those potential side-effects. He also administers high doses of vitamin B2 (riboflavin). A significant part of the world population (10-15%) are not able to absorb enough vitamin B2 from normal daily doses to enable the chemical reactions within the body that convert D3 into the working form of vitamin D for immune function - 1,25HydroxyD. 

After his patients have been at the correct blood level of PTH for 2-3 months, most if not all of the symptoms are gone, depending on whether permanent disabilities were already established before the beginning of vitamin D therapy. They are considered to be in remission as they no longer have relapses, nor new lesions in their MRI images. They no longer expect to be blind or paraplegic, or to become disabled. They have their life back! 

After the third or fourth appointment, Coimbra recommends his patients return in 2 years and again in 5 years for a review appointment and to make sure that no further adjustment of their vitamin D dosage is necessary. Right now most patients are still on very high doses of vitamin D (in some cases levels up to or even higher than 4,000 ng/mL are required to maintain PTH around its lowest normal level and suppressed disease activity due to their very high degree of resistance to both beneficial and toxic effects of vitamin D; in most patients the circulating levels are within the range of 250-1,000 ng/mL). He has not been practicing long enough to determine how long high circulating levels of vitamin D have to be maintained to keep MS in remission. 


Do you think it was the chicken or the egg? Does low vitamin D cause MS? Or does MS cause low vitamin D? 

Coimbra feels low vitamin D associated with genetically inherited vitamin D resistance and stressful life events trigger MS and other autoimmune disorders. Vitamin D is a natural, powerful inhibitor of autoimmune reactions. He cites latitude charts of MS incidence (the farther you are from the equator - the more prevalent the disease) as the initial epidemiological data which triggered intensive research and cumulative evidence - enabling development of his protocol. 

Sunday, April 30, 2017

How Does MS Affect Your Sleep?


                                                                  
  
Click here to receive MS news via e-mail



How Does MS Affect Your Sleep?

Profile photo of Calie Wyatt
 
Fatigue is one of the most common and frustrating symptoms that comes along with multiple sclerosis. In MS there is both fatigue and what is known as lassitude. While fatigue can itself feel debilitating, lassitude is the more severe type of MS fatigue. Lassitude is defined as, “A state of physical or mental weariness; lack of energy.” Nationalmssociety.org gives several examples of lassitude and how it is different from the type of fatigue experienced by people without MS. Here are the examples of lassitude and how it affects us that they have listed:
  • Generally occurs on a daily basis
  • May occur in the morning, even after a restful night’s sleep
  • Tends to worsen as the day progresses
  • Is often aggravated by heat or humidity
  • Comes on easily and suddenly
  • Is generally more severe than common fatigue
  • Is more likely to interfere with daily responsibilities
My biggest symptom and largest hurdle with MS is my fatigue, and sometimes lassitude. It has always baffled me how I can be so incredibly tired all day long, and as soon as I climb into bed my mind won’t shut off enough to let my body rest. I have had trouble sleeping for as long as I can remember. Cue the counting sheep-in fact, many nights I have to count as high as I can until I finally drift off. Many things can affect your ability to sleep, but side effects from medication and stress were once my biggest issues. I no longer have issues sleeping because of those things, but it is still extremely difficult for me to close my eyes and fall asleep like any other person. I often have to take an over the counter sleep medication just to fall asleep, otherwise it will take me hours trying to do it on my own. I have heard from several doctors that MS and insomnia are not directly related. However many MS symptoms, such as spasticity, frequent trips to the bathroom, temperature dysregulation (hello, hot flashes) and medications can most certainly disturb your sleep. It is also noted that damage to our key neurological functions can disrupt our basic physiological processes, including maintenance of regular sleep-wake cycles.



MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

More on handicapped parking issues - Looking Beyond


                                                                  
  
Click here to receive MS news via e-mail


Profile photo of Devin Garlit
 
Recently, I came across yet another story from a friend with MS about how they were discriminated against because of their handicapped parking placard. This is such a disheartening thing to read, and it’s something I keep hearing more and more about. You’ve no doubt heard or experienced it yourself: a nosy person sees you parking in a handicapped spot, can’t mind their own business, thinks they are the righteous hand of mob justice, and then confronts the person using the spot, never considering that the person, despite what they see, may suffer from an invisible illness. It’s devastating to those of us it’s happened to. With this scenario playing out time and time again, I wanted to again plead with folks to please look past what you see on the surface.
Of course the issue extends past handicapped parking. I was also recently reminded of a person who gave me one of those classic, tilted head responses of “really?” when I explained I was on disability because of MS. Yeah, yeah, yeah, but I look so good right? Many of us battling invisible symptoms have to deal with this on an almost daily basis. The tilted heads, the questions, the looks of disbelief. Trust me, I can’t work, I’ve tried. No matter what you think, not being able to work is a lot harder than actually working. Always remember, if you see me, in person or even in a picture on social media, that’s me at my very best. You don’t see the aftermath (when I’m paying that exorbitant MS Tax) or me at my worst.
It’s not all about invisible symptoms either. Even more problems can occur when we are using a cane or wheelchair. Especially when we are on the younger side. It can be a very unexpected sight for many people, a younger person in a wheelchair or with a cane. People want to gawk, they want to stare. They also want to know why. I was recently using my cane and a man came up and asked me, “rough motorcycle accident?” and then I explained the MS. He was embarrassed and said that because of my beard he assumed it must have been something like a motorcycle accident. I actually got a good laugh over that. My appearance doesn’t fit the mold of what people think MS looks like. That’s the thing though, there is no MS mold, we’re all little snowflakes in this disease, all very different. Perhaps more than any other disease, MS has a wide range of symptoms and demographics.
This isn’t only an issue between those of us with MS and those without. Because of the wide variety of symptoms, there can sometimes be issues among ourselves. A person in a wheelchair may think that another person with MS has it easy because they can walk fine. I’ve seen this cause issues among MS groups and it’s crazy. We of all people should recognize the invisible nature of this disease and that just because a person isn’t in a wheelchair, doesn’t mean they aren’t suffering. We have to remember that no matter what symptoms a person has, we’re in this together.
READ MORE


MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis